Glen Eagle Advisors’s Cytokinetics CYTK Stock Holding History

Glen Eagle Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	-$3.57K	–	973
2021 Q3	$3.57K	Hold	100	–	–	﹤0.01%	851
2021 Q2	$1.98K	Hold	100	–	–	﹤0.01%	917
2021 Q1	$2.33K	Buy	+100	New	+$2.13K	﹤0.01%	867
2019 Q4	–	Sell	-125	Closed	-$1.42K	–	907
2019 Q3	$1.42K	Hold	125	–	–	﹤0.01%	737
2019 Q2	$1.41K	Hold	125	–	–	﹤0.01%	718
2019 Q1	$1.01K	Hold	125	–	–	﹤0.01%	694
2018 Q4	$790	Hold	125	–	–	﹤0.01%	687
2018 Q3	$1.23K	Hold	125	–	–	﹤0.01%	660
2018 Q2	$1.04K	Hold	125	–	–	﹤0.01%	653
2018 Q1	$900	Hold	125	–	–	﹤0.01%	646
2017 Q4	$1.02K	Hold	125	–	–	﹤0.01%	604
2017 Q3	$1.81K	Buy	+125	New	+$1.71K	﹤0.01%	586

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Glen Eagle Advisors's CYTK Position: Q4 2021 in Review

Glen Eagle Advisors sold out of Cytokinetics (CYTK) in Q4 2021, closing a stake of 100 shares — an estimated $3.57K sold.

Glen Eagle Advisors first reported a position in CYTK in Q3 2017 and held it in 12 quarters. The position peaked at $3.57K in Q3 2021. 250 funds tracked by Wall St. Rank hold CYTK as of Q4 2021.

Glen Eagle Advisors reported no remaining Cytokinetics position as of Q4 2021 after selling out during the quarter.
Glen Eagle Advisors sold 100 Cytokinetics shares in Q4 2021, an estimated $3.57K.
Glen Eagle Advisors first reported a position in Cytokinetics in Q3 2017 and held it in 12 quarters.
Glen Eagle Advisors's Cytokinetics position peaked at $3.57K in Q3 2021.
250 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2021.

Based on Glen Eagle Advisors's 13F filing for Q4 2021, filed 13 Aug 2024.